Roche Digs In To Early Breast Cancer With New Perjeta Approvals
Better than expected FDA labeling for rising star Perjeta in neoadjuvant (before surgery) and adjuvant (after surgery) breast cancer could boost sales greatly beyond expectations, some analysts say.
You may also be interested in...
KATHERINE supports filings for earlier use of Kadyla in adjuvant setting of breast cancer.
Puma Biotech has proven to be the cat with nine lives after its HER2+ breast cancer treatment neratinib received a u-turn from CHMP, granting it a positive trend vote. But even if final marketing approval is granted this year, European prospects don’t necessarily follow.
The latest drug development news and highlights from our Performance Tracker.